Trial Profile
A Phase III, Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of MK-6621 in Patients With Atrial Fibrillation
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Registrational; Therapeutic Use
- Sponsors Correvio Pharma; Merck Sharp & Dohme
- 14 Aug 2018 According to a Cardiome Pharma media release, the China Food and Drug Administrations (CFDA) Center for Drug Evaluation (CDE) selected Brinavess as potentially eligible for priority review in China.Also, Brinavess was named one of 48 drugs deemed clinically urgent and targeted for expedited clearance based on existing ex-china clinical data which included positive results from this trial.
- 07 Nov 2014 Primary endpoint has been met (conversion to sinus rhythm, assessed within 90 minutes after first exposure), according to a Cardiome Pharma media release.
- 07 Nov 2014 Results published in a Cardiome Pharma media release.